A year after her diagnosis with ovarian cancer in May 2011, Dr. Jan Byrne began looking for ways to be more involved in ovarian cancer advocacy and education. She connected with the Ovarian Cancer National Alliance and realized that there was a need for more services in Utah. “There wasn’t anything organized here for ovarian … Continued
(January 28, 2015) OCRF grantee Ron Chandler, PhD developed a mouse model of clear cell ovarian cancer and found a potential route to better treatments and much-needed diagnostic screens. Dr. Chandler spearheaded a team of researchers at University of North Carolina that developed a mouse model of clear cell ovarian cancer that accurately portrays the … Continued
(January 26, 2015) Use of the PARP inhibitor veliparib in combination with oral cyclophosphamide did not result in an improvement in response rate or median progression-free survival compared with treatment with cyclophosphamide alone, according to a phase II study evaluating patients with high-grade serous ovarian cancer, peritoneal, fallopian tube, and BRCA-mutant ovarian cancers. The research was … Continued
(January 22, 2015) In a study published in Clinical Cancer Research, researchers analyzed the effect of germline mutations in BRCA1 and BRCA2 on mortality in ovarian cancer patients up to ten years after diagnosis. The researchers found that BRCA1/2 mutations are associated with better short-term survival, but this advantage decreases over time and, in BRCA1 … Continued
The Cancer Genome Atlas (TCGA), a massive U.S. effort to genetically profile 10,000 tumors, has officially come to an end. The National Cancer Institute (NCI) has announced that it will continue to intensively sequence tumors in three cancers, ovarian, colorectal and lung adenocarcinoma, with an expanded scope that incorporates detailed clinical information about the patient’s … Continued
A new study published in Gynecologic Oncology found that palliative care consultation is associated with improvement in symptom burden, the majority of which occurs within one day of consultation. Palliative care (or treatment) relieves symptoms such as pain, and reduces the suffering caused by cancer. Its main purpose is to keep the best quality of life … Continued
Starting the new year with a mission to fund ovarian cancer research Friday, January 2nd, 2015 – New York, NY Amrita Singh Jewelry is proud to announce a new initiative for the new year – a special capsule collection with a percentage of sales going to Ovarian Cancer Research Fund. Nearly 200,000 women in the … Continued
(December 19, 2014) The U.S. Food and Drug Administration (FDA) has approved AstraZeneca’s Olaparib (Lynparza) for advanced, BRCA-mutated ovarian cancer, the first approval of a drug in the PARP (poly ADP-ribose polymerase) inhibitor class. The FDA also approved Myriad Genetics’ BRACAnalysis CDx test to determine patients’ BRCA status as a companion diagnostic for determining whether … Continued
When Diane Riche’s mother was diagnosed with ovarian cancer in 2010, Diane turned to the internet for information. Through her research she came to the Alliance’s website, where she learned that ovarian cancer does in fact have symptoms. Diane recalls thinking: “What do you mean ‘Know the symptoms’? There are no symptoms for ovarian cancer!” … Continued
(12/14/14) | In 2014, with your generous support OCRF grantees made significant advances in the fight against ovarian cancer, including: Thank you for supporting our mission to fund scientific research that will lead to more effective identification, treatment, and ultimately a cure for this terrible disease.
(December 10, 2014) OCRF Ann Schreiber Mentored Investigator Award Grantee, Pradeep Chaluvally-Raghavan, Ph.D., and other researchers at The University of Texas MD Anderson Cancer Center believe they may have found a molecule-based approach to halting the destructive nature of a genetic misfire called the 3q26.2 amplicon. The research was funded in part by a grant … Continued
Population-based testing for BRCA 1/2 gene mutations detects the high proportion of carriers not identified by cancer family history (FH)-based testing. A new study published in the Journal of the National Cancer Institute compared the cost-effectiveness of population-based BRCA testing with the standard FH-based approach in Ashkenazi Jewish (AJ) women. The study found that population-based … Continued
Get email updates about research news, action alerts, and ways to join the fight.
